Q2 2026 Holdings
Filed 2026-08-14 | 73 holdings | $213.8M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| KLA Corporation(KLAC) | COM NEW | 482480100 | $53.8M | 178,471 | 25.2% |
| Bristol-Myers Squibb Co(BMY) | COM | 110122108 | $17.1M | 297,243 | 8.0% |
| LAM Research Corporation(LRCX) | COM NEW | 512807306 | $15.2M | 35,000 | 7.1% |
| Intellia Therapeutics Inc(NTLA) | 45826J105 | 45826J105 | $6.8M | 385,900 | 3.2% |
| Solid Biosciences Inc(SLDB) | COM NEW | 83422E204 | $6.7M | 666,196 | 3.1% |
| Biodesix Inc | COM | 09075X108 | $6.5M | 286,804 | 3.0% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $5.8M | 178,110 | 2.7% |
| Ovintiv Inc(OVV) | COM | 69047Q102 | $5.7M | 107,500 | 2.6% |
| Nektar Therapeutics(NKTR) | COM | 640268306 | $5.7M | 81,000 | 2.6% |
| Corcept Therapeutics Inc(CORT) | COM | 218352102 | $5.0M | 57,200 | 2.3% |
| Neurocrine Biosciences Inc(NBIX) | COM | 64125C109 | $4.6M | 27,190 | 2.1% |
| Prothena Corp PLC(PRTA) | SHS | G72800108 | $4.4M | 449,019 | 2.1% |
| Acadia Pharmaceuticals Inc(ACAD) | COM | 004225108 | $4.3M | 171,000 | 2.0% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $4.3M | 35,018 | 2.0% |
| Compass Therapeutics Inc(CMPX) | COM | 20454B104 | $3.7M | 1,675,000 | 1.7% |
| Relmada Therapeutics Inc(RLMD) | COM | 75955J402 | $2.8M | 408,100 | 1.3% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $2.6M | 50,000 | 1.2% |
| Halozyme Therapeutics Inc(HALO) | COM | 40637H109 | $2.6M | 33,251 | 1.2% |
| Celldex Therapeutics Inc(CLDX) | COM NEW | 15117B202 | $2.6M | 69,900 | 1.2% |
| Cytokinetics Inc(CYTK) | COM | 23282W605 | $2.6M | 30,000 | 1.2% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $2.5M | 199,000 | 1.2% |
| Vera Therapeutics Inc(VERA) | CL A | 92337R101 | $2.5M | 57,758 | 1.2% |
| United Therapeutics Corp(UTHR) | COM | 91307C102 | $2.4M | 4,506 | 1.1% |
| Zenas Biopharma Inc(ZBIO) | COM | 98937L105 | $2.4M | 93,601 | 1.1% |
| Uniqure NV(QURE) | SHS | N90064101 | $2.3M | 50,697 | 1.1% |
| Pacific Biosciences of California Inc(PACB) | COM | 69404D108 | $2.3M | 1,350,000 | 1.1% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $2.3M | 17,000 | 1.1% |
| VIR Biotechnology Inc(VIR) | COM | 92764N102 | $2.2M | 220,000 | 1.0% |
| Biogen Inc(BIIB) | COM | 09062X103 | $1.9M | 9,000 | 0.9% |
| EQT Corporation(EQT) | COM | 26884L109 | $1.8M | 34,619 | 0.9% |
| Bioage Labs Inc(BIOA) | COM | 09077V100 | $1.7M | 69,000 | 0.8% |
| Travere Therapeutics Inc(TVTX) | COM | 89422G107 | $1.6M | 29,000 | 0.8% |
| Quidelortho Corp | COM | 74838J101 | $1.6M | 89,377 | 0.7% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $1.5M | 6,000 | 0.7% |
| Foghorn Therapeutics Inc(FHTX) | COM | 344174107 | $1.4M | 281,937 | 0.6% |
| Bicycle Therapeutics PLC(BCYC) | SPONSORED ADS | 088786108 | $1.3M | 313,616 | 0.6% |
| Structure Therapeutics Inc(GPCR) | SPONS ADR | 86366E106 | $1.3M | 24,000 | 0.6% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $1.3M | 21,032 | 0.6% |
| Novo Nordisk A/S(NVO) | ADR | 670100205 | $1.2M | 24,000 | 0.5% |
| Freeport-Mcmoran CL(FCX) | CL-B | 35671D857 | $1.1M | 18,035 | 0.5% |
| Immunome Inc(IMNM) | COM | 45257U108 | $1.1M | 50,000 | 0.5% |
| Pharvaris N V(PHVS) | COM | N69605108 | $1.0M | 29,847 | 0.5% |
| Harrow Health Inc(HROW) | COM | 415858109 | $1.0M | 24,000 | 0.5% |
| Adagene Inc(ADAG) | ADS | 005329107 | $1.0M | 240,000 | 0.5% |
| Definium Therapeutics Inc(DFTX) | COM SHS | 24477V105 | $940.8K | 20,000 | 0.4% |
| Silence Therapeutics PLC(SLN) | ADS | 82686Q101 | $782.0K | 71,218 | 0.4% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $651.0K | 8,741 | 0.3% |
| 4D Molecular Therapeutics Inc(FDMT) | COM | 35104E100 | $645.1K | 48,505 | 0.3% |
| Urogen Pharma LTD(URGN) | COM | M96088105 | $606.7K | 16,487 | 0.3% |
| Phathom Pharmaceuticals Inc(PHAT) | COM | 71722W107 | $596.8K | 55,000 | 0.3% |